Results 111 to 120 of about 29,547 (250)

Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence

open access: yes
International audienceBackgroundCombined hepatocholangiocarcinoma is a rare cancer with a grim prognosis composed of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma morphologic patterns in the same tumor.
Boleslawski, Emmanuel   +135 more
core   +1 more source

Optimal Stenting Strategy During Chemotherapy: Impact of Time to First Reintervention on Survival in Malignant Hilar Biliary Obstruction

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Advances in chemotherapy have increased survival in biliary tract cancer patients, and reports of the effectiveness of neoadjuvant therapy are emerging. Accordingly, developing optimal drainage strategies under chemotherapy is important.
Katsuhiko Sato   +8 more
wiley   +1 more source

Case report: Rare observation of thyroid-like cholangiocarcinoma

open access: yesFrontiers in Medicine
Intrahepatic cholangiocarcinoma is a highly malignant tumor with a poor prognosis. Radical surgical resection remains the “gold standard” for improving patient outcomes; however, only a minority of patients qualify for this approach.
Ekaterina Bondarenko   +5 more
doaj   +1 more source

Differentiating the Clinical and Variant Spectrum of Hardikar Syndrome From Other MED12 ‐Related Developmental Disorders

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 7, Page 1619-1650, July 2026.
ABSTRACT The rare X‐linked female‐restricted Hardikar syndrome (HDKR, OMIM # 301068) is characterized by multiple congenital anomalies including orofacial clefts, gastrointestinal, genitourinary, and cardiac anomalies, but cognitive and neurobehavioral development is rarely impaired.
Tinne Warmoeskerken   +4 more
wiley   +1 more source

Impact of Multimodal Oncological Therapy on Survival and Local Control in Unresectable Perihilar Cholangiocarcinoma

open access: yesCancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Background This study aimed to evaluate the safety and effectiveness of targeted multimodal oncological therapy in patients with unresectable hilar cholangiocarcinoma (HCCA) presenting with obstructive jaundice, particularly those with the nodular‐infiltrating morphological type.
Zhen Chi   +5 more
wiley   +1 more source

Short-term and Long-term Clinical Outcomes of Combined Caudate Lobectomy for Intrahepatic Cholangiocarcinoma Involving the Hepatic Hilus: A Propensity Score Analysis

open access: yesGut and Liver
Background/Aims: Extended hepatectomy combined with caudate lobe resection has been approved for the radical resection of hilar cholangiocarcinoma. There was a lack of credible research on the clinical value of caudate lobectomy (CL) for intrahepatic ...
Di Zeng   +5 more
doaj   +1 more source

Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma. [PDF]

open access: yesHistopathology
Differentiating intrahepatic CCA from PDAC metastatic to the liver is critical for the clinical management of patients with pancreatobiliary cancers. AQP1 has demonstrated an excellent discriminatory performance in this clinical scenario. Aims Differentiating intrahepatic cholangiocarcinoma (iCCA) from metastatic ductal adenocarcinoma of the pancreas ...
Giuseppe L   +7 more
europepmc   +2 more sources

Intrahepatic Cholangiocarcinoma Associated with Intrahepatic Duct Stones

open access: yes, 2009
ObjectiveIt has been well established that the long-term prognosis of intrahepatic duct stones (IHDS) is complicated by the late development of biliary cirrhosis with associated intrahepatic cholangiocarcinoma (IHCC).
Jong-Man Won   +11 more
core   +1 more source

RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy